Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 77

1.

Identifying high risk individuals for targeted lung cancer screening: Independent validation of the PLCOM2012 risk prediction tool.

Weber M, Yap S, Goldsbury D, Manners D, Tammemagi M, Marshall H, Brims F, McWIlliams A, Fong K, Kang YJ, Caruana M, Banks E, Canfell K.

Int J Cancer. 2017 Mar 1. doi: 10.1002/ijc.30673. [Epub ahead of print]

PMID:
28249359
2.

Identifying incident colorectal and lung cancer cases in health service utilisation databases in Australia: a validation study.

Goldsbury D, Weber M, Yap S, Banks E, O'Connell DL, Canfell K.

BMC Med Inform Decis Mak. 2017 Feb 27;17(1):23. doi: 10.1186/s12911-017-0417-5.

3.

Time to clinical investigation for Indigenous and non-Indigenous Queensland women after a high grade abnormal Pap smear, 2000-2009.

Whop LJ, Baade PD, Brotherton JM, Canfell K, Cunningham J, Gertig D, Lokuge K, Garvey G, Moore SP, Diaz A, O'Connell DL, Valery P, Roder DM, Condon JR.

Med J Aust. 2017 Feb 6;206(2):73-77.

PMID:
28152354
4.

Optimal Management Strategies for Primary HPV Testing for Cervical Screening: Cost-Effectiveness Evaluation for the National Cervical Screening Program in Australia.

Simms KT, Hall M, Smith MA, Lew JB, Hughes S, Yuill S, Hammond I, Saville M, Canfell K.

PLoS One. 2017 Jan 17;12(1):e0163509. doi: 10.1371/journal.pone.0163509.

5.

Eurogin 2016 Roadmap: how HPV knowledge is changing screening practice.

Wentzensen N, Arbyn M, Berkhof J, Bower M, Canfell K, Einstein M, Farley C, Monsonego J, Franceschi S.

Int J Cancer. 2017 May 15;140(10):2192-2200. doi: 10.1002/ijc.30579. Epub 2017 Jan 11. Review.

PMID:
28006858
6.

Impact of the Australian National Cervical Screening Program in women of different ages.

Smith M, Canfell K.

Med J Aust. 2016 Oct 17;205(8):359-364.

PMID:
27736623
7.

Resilience of a FIT screening programme against screening fatigue: a modelling study.

Greuter MJ, Berkhof J, Canfell K, Lew JB, Dekker E, Coupé VM.

BMC Public Health. 2016 Sep 22;16(1):1009.

8.

Will cervical screening remain cost-effective in women offered the next generation nonavalent HPV vaccine? Results for four developed countries.

Simms KT, Smith MA, Lew JB, Kitchener HC, Castle PE, Canfell K.

Int J Cancer. 2016 Dec 15;139(12):2771-2780. doi: 10.1002/ijc.30392.

PMID:
27541596
9.

The molecular characteristics of colonic neoplasms in serrated polyposis: a systematic review and meta-analysis.

He EY, Wyld L, Sloane MA, Canfell K, Ward RL.

J Pathol Clin Res. 2016 Apr 22;2(3):127-37. doi: 10.1002/cjp2.44. Review.

10.

Past cervical intraepithelial neoplasia grade 3, obesity, and earlier menopause are associated with an increased risk of vulval cancer in postmenopausal women.

Coffey K, Gaitskell K, Beral V, Canfell K, Green J, Reeves G, Barnes I.

Br J Cancer. 2016 Aug 23;115(5):599-606. doi: 10.1038/bjc.2016.165.

PMID:
27336599
11.

Effectiveness Modelling and Economic Evaluation of Primary HPV Screening for Cervical Cancer Prevention in New Zealand.

Lew JB, Simms K, Smith M, Lewis H, Neal H, Canfell K.

PLoS One. 2016 May 17;11(5):e0151619. doi: 10.1371/journal.pone.0151619.

12.

The first comprehensive report on Indigenous Australian women's inequalities in cervical screening: A retrospective registry cohort study in Queensland, Australia (2000-2011).

Whop LJ, Garvey G, Baade P, Cunningham J, Lokuge K, Brotherton JM, Valery PC, O'Connell DL, Canfell K, Diaz A, Roder D, Gertig D, Moore SP, Condon JR.

Cancer. 2016 May 15;122(10):1560-9. doi: 10.1002/cncr.29954.

13.

Transitioning from cytology-based screening to HPV-based screening at longer intervals: implications for resource use.

Smith MA, Gertig D, Hall M, Simms K, Lew JB, Malloy M, Saville M, Canfell K.

BMC Health Serv Res. 2016 Apr 26;16:147. doi: 10.1186/s12913-016-1375-9.

14.

Cervical Abnormalities Are More Common among Indigenous than Other Australian Women: A Retrospective Record-Linkage Study, 2000-2011.

Whop LJ, Baade P, Garvey G, Cunningham J, Brotherton JM, Lokuge K, Valery PC, O'Connell DL, Canfell K, Diaz A, Roder D, Gertig DM, Moore SP, Condon JR.

PLoS One. 2016 Apr 11;11(4):e0150473. doi: 10.1371/journal.pone.0150473.

15.

Use of Menopausal Hormone Therapy and Bioidentical Hormone Therapy in Australian Women 50 to 69 Years of Age: Results from a National, Cross-Sectional Study.

Velentzis LS, Banks E, Sitas F, Salagame U, Tan EH, Canfell K.

PLoS One. 2016 Mar 23;11(3):e0146494. doi: 10.1371/journal.pone.0146494.

16.

Impact of HPV sample self-collection for underscreened women in the renewed Cervical Screening Program.

Smith M, Lew JB, Simms K, Canfell K.

Med J Aust. 2016 Mar 21;204(5):1941e-7.

PMID:
26985849
17.

Using probabilistic record linkage methods to identify Australian Indigenous women on the Queensland Pap Smear Register: the National Indigenous Cervical Screening Project.

Whop LJ, Diaz A, Baade P, Garvey G, Cunningham J, Brotherton JM, Canfell K, Valery PC, O'Connell DL, Taylor C, Moore SP, Condon JR.

BMJ Open. 2016 Feb 12;6(2):e009540. doi: 10.1136/bmjopen-2015-009540.

18.

Trends in genital warts by socioeconomic status after the introduction of the national HPV vaccination program in Australia: analysis of national hospital data.

Smith MA, Liu B, McIntyre P, Menzies R, Dey A, Canfell K.

BMC Infect Dis. 2016 Feb 1;16:52. doi: 10.1186/s12879-016-1347-z.

19.

Menopausal hormone therapy use and breast cancer risk in Australia: Findings from the New South Wales Cancer, Lifestyle and Evaluation of Risk study.

Salagame U, Banks E, Sitas F, Canfell K.

Int J Cancer. 2016 Apr 15;138(8):1905-14. doi: 10.1002/ijc.29942.

PMID:
26599391
20.

Long-Term Impact of the Dutch Colorectal Cancer Screening Program on Cancer Incidence and Mortality-Model-Based Exploration of the Serrated Pathway.

Greuter MJ, Demirel E, Lew JB, Berkhof J, Xu XM, Canfell K, Dekker E, Meijer GA, Coupé VM.

Cancer Epidemiol Biomarkers Prev. 2016 Jan;25(1):135-44. doi: 10.1158/1055-9965.EPI-15-0592.

Supplemental Content

Loading ...
Support Center